Cellebrite DI

Company Profile

Cellebrite DI had its IPO on 2021-08-31 under the ticker symbol CLBT.

The company operates in the Technology sector and Software-Infrastructure industry. Cellebrite DI has a staff strength of 0 employees.

Stock update

Shares of Cellebrite DI opened at $5.77 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $5.72 - $5.88, and closed at $5.86.

This is a +0.69% increase from the previous day's closing price.

A total volume of 153,629 shares were traded at the close of the day’s session.

In the last one week, shares of Cellebrite DI have increased by +0.51%.

Cellebrite DI's Key Ratios

Cellebrite DI has a market cap of $1.10 billion, indicating a price to book ratio of 13.6828 and a price to sales ratio of 3.0683.

In the last 12-months Cellebrite DI’s revenue was $270.65 million with a gross profit of $219.91 million and an EBITDA of $10.24 million. The EBITDA ratio measures Cellebrite DI's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cellebrite DI’s operating margin was 0.39% while its return on assets stood at 0.18% with a return of equity of 46.64%.

In Q4, Cellebrite DI’s quarterly earnings growth was a negative -85.3% while revenue growth was a positive 9%.

Cellebrite DI’s PE and PEG Ratio

Forward PE

37.1747

Trailing PE

9.8644

PEG

Its diluted EPS in the last 12-months stands at $0.59 per share while it has a forward price to earnings multiple of 37.1747 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cellebrite DI’s profitability.

Cellebrite DI stock is trading at a EV to sales ratio of 2.5216 and a EV to EBITDA ratio of 163.4949. Its price to sales ratio in the trailing 12-months stood at 3.0683.

Cellebrite DI stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$403.29 million

Total Liabilities

$207.78 million

Operating Cash Flow

$0

Capital Expenditure

$3.18 million

Dividend Payout Ratio

0%

Cellebrite DI ended 2023 with $403.29 million in total assets and $0 in total liabilities. Its intangible assets were valued at $403.29 million while shareholder equity stood at $73.87 million.

Cellebrite DI ended 2023 with $0 in deferred long-term liabilities, $207.78 million in other current liabilities, in common stock, $199.24 million in retained earnings and $26.83 million in goodwill. Its cash balance stood at $87.65 million and cash and short-term investments were $183.62 million. The company’s total short-term debt was $5,003,000 while long-term debt stood at $0.

Cellebrite DI’s total current assets stands at $295.93 million while long-term investments were $22.13 million and short-term investments were $95.98 million. Its net receivables were $78.76 million compared to accounts payable of $4.61 million and inventory worth $10.18 million.

In 2023, Cellebrite DI's operating cash flow was $0 while its capital expenditure stood at $3.18 million.

Comparatively, Cellebrite DI paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$5.86

52-Week High

$7.31

52-Week Low

$3.8

Analyst Target Price

$7.48

Cellebrite DI stock is currently trading at $5.86 per share. It touched a 52-week high of $7.31 and a 52-week low of $7.31. Analysts tracking the stock have a 12-month average target price of $7.48.

Its 50-day moving average was $5.5 and 200-day moving average was $4.95 The short ratio stood at 7.54 indicating a short percent outstanding of 0%.

Around 7686.2% of the company’s stock are held by insiders while 1830% are held by institutions.